Everyone says they want more affordable drugs for patients that need them, but people disagree quite a bit on who’s to blame for the current status quo of sky-high prescription prices – not to mention how they might be corrected.

To help unpack some of those trends and conflicting perspectives, Brandon Newman, CEO of healthcare analytics firm Xevant, joins host Jonah Comstock on today’s episode of the pharmaphorum podcast. They discuss the oft-maligned role of pharmacy benefit managers, problems with the drug pricing provisions in the Inflation Reduction Act, the lack of (and importance of) price transparency, the various levers available to the government to address prices, and what companies like Xevant are doing right now to lower drug prices for patients.

Leave a Reply

Your email address will not be published. Required fields are marked *